Cognito Therapeutics
@cognitotx
Followers
995
Following
159
Media
41
Statuses
314
Cognito Therapeutics is developing a novel device-based approach to treating Alzheimer’s disease. Learn about our pivotal study: https://t.co/yTzyuGOAaD
Cambridge, MA
Joined November 2016
Excited to announce our new data from the OVERTURE study at @adpdnet for #Spectris in #Alzheimers disease. 🧠🧠. Read our press release: .
1
0
1
RT @Sid_Healthcare: .@CognitoTx Therapeutics completes enrollment in study of #neuromodulation for #Alzheimers
0
1
0
RT @MPOmagazine: Analysis indicates @cognitotx neuromodulation therapy delays #Alzheimers disease progression: http….
0
1
0
RT @PhylFerrell: How many times do you go to a #healthcare conference… learn something new AND get a full-on belly laugh? Highly recommend….
0
1
0
RT @fwhealthtech: Cognito Therapeutics' neuromod helps Alzheimer's patients hold onto memories longer $CGTX @cognitotx #neuromodulation #ne….
0
1
0
RT @AIforGood: Another inspiring voice joining the #AIforGood Global Summit 2025! Join us as Christian F. Howell, CEO of @cognitotx, shares….
0
2
0
RT @gt_neuro: The first day of #InterfaceNeuroGT is wrapping up with a presentation from the generous sponsors of our meeting: @protocollab….
0
1
0
.@fwhealthtech covers our recent #ADPD25 results for #Spectris in #Alzheimers. 🧠🧠. Read the article: .
0
0
0
RT @neurology_live: What role does Gamma stimulation therapy have in the treatment of AD🧐? How does a physics-based approach differ from wh….
0
2
0
Our CEO Christian Howell will be presenting on March 10 at 10.30 am ET at the #InvestivalShowcase 2025. @LSXLeaders .More info:.
0
1
1
RT @Being_Patient_: 🧠 Emerging treatments are coming online for #Alzheimers, developed with the goal of clearing harmful plaques and impro….
0
1
0
We’re excited to sponsor the 6th Bioelectronic Medicine Summit on March 4-5 in New York. Our CMO Dr. Ralph Kern will be giving a keynote on March 5 at 8.45 am ET. 🧠🧠. More info: .
0
0
2
We’re excited to welcome 4 key leadership appointments to accelerate the company’s growth, clinical advancement, and commercialization. Welcome to the Cognito team! 🙌🙌.
1
0
3
We announced the publication of a study in Alzheimer's & Dementia: Translational Research & Clinical Interventions that highlights myelin and synaptic biomarker changes in #Alzheimer’s patients treated with our non-invasive medical device, Spectris™. 🧠.
0
0
1
RT @IdeagenGlobal: Available today: Ideagen's Catalyze Impact Weekly Podcast—spotlighting leaders driving change across industries!. Ep. 6….
0
1
0
RT @Being_Patient_: Dr. Michelle Papka, Founder and President of The Cognitive and Research Center of New Jersey joins us to discuss emergi….
0
3
0
The Outcomes Rocket podcast speaks with our CEO Christian Howell: .
0
1
1
Excited to present our early-stage cost-effectiveness analysis of its Spectris™ therapy for Alzheimer’s disease (AD) at the International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR Europe) 2024 Annual Meeting in Barcelona, Spain.
0
2
3
Sharing our new paper in @FrontiersIn Neurology titled “Spectris™ Treatment Preserves Corpus Callosum Structure in Alzheimer’s Disease,” highlights the potential of Cognito’s Spectris™ as a disease-modifying candidate for #Alzheimer’s disease (AD).
0
0
1
Our CEO Christian Howell will be on a panel on #Alzheimers at #BioFuture2024! Join him and other industry experts as we explore the latest topics and innovations shaping the future of #healthcare. For more info, visit
0
0
1